CD73-targeted CAR-NK cell therapy displays potent antitumor activity and translational potential in relapsed/refractory lung adenocarcinoma
Preclinical evidence is provided that CD73-CAR-NK cells exhibit potent antitumor efficacy for R/R LUAD through their dual functions of eliminating CD73-high tumor cells and resisting adenosine-mediated immunosuppressive signaling, supporting their therapeutic potential.